文献速递皮肤肿瘤

丑小鸭征是黑色素瘤检测效率的主要因素

Ugly Duckling Sign as a Major Factor of Efficiency in Melanoma Detection.
PubMed 文献 · JAMA Dermatol · 2017-01-01

该研究评估皮肤科医生对丑小鸭征识别的一致性,并估计患者内对比分析(IPCA)对黑色素瘤诊断的贡献。结果显示,所有黑色素瘤均被9名医生标记为丑小鸭痣和形态学可疑痣;IPCA特异性高于病灶聚焦分析,且联合IPCA可使活检痣数量减少6.9倍。

要点

  • 所有黑色素瘤均被标记为丑小鸭痣和形态学可疑痣。
  • IPCA特异性临床图像为0.96,皮肤镜图像为0.95,高于病灶聚焦分析。
  • 联合IPCA与病灶聚焦分析使活检痣数量减少6.9倍。

核心结论

  • 患者内对比分析对黑色素瘤诊断效率至关重要。
  • 在计算机辅助诊断系统中引入基于丑小鸭征的IPCA有望提高性能。

研究设计与样本

  • 研究纳入80例患者(平均年龄42岁,范围19-80岁;33男47女)的2089张临床痣图像,以及30例患者(平均年龄40岁,范围21-75岁;12男18女)的766张皮肤镜图像。
  • 同一批9名皮肤科医生在2011年9月22日至2013年4月1日期间对图像进行盲法评估。

主要发现

  • 9名医生将所有黑色素瘤均标记为丑小鸭痣和形态学可疑痣。
  • 临床图像中每例患者丑小鸭痣的中位数为0.8(均值1.0,范围0.48-2.03),皮肤镜图像中为1.26(均值1.4,范围1.00-2.06)。
  • 医生对丑小鸭痣的识别一致性在皮肤镜图像中较低(临床图像平均配对一致性0.53,皮肤镜图像0.50)。
  • IPCA特异性临床图像为0.96、皮肤镜图像为0.95,病灶聚焦分析分别为0.88和0.85。
  • 联合IPCA与病灶聚焦分析时,考虑活检的痣数量比单独病灶聚焦分析减少6.9倍。

关键数值与推荐

  • 临床图像中每例患者丑小鸭痣中位数0.8(均值1.0,范围0.48-2.03)。
  • 皮肤镜图像中每例患者丑小鸭痣中位数1.26(均值1.4,范围1.00-2.06)。
  • IPCA特异性临床图像0.96、皮肤镜图像0.95;病灶聚焦分析特异性临床图像0.88、皮肤镜图像0.85。
  • 联合分析使活检痣数量减少6.9倍。

临床怎么用

  • 在黑色素瘤筛查中应常规进行患者内对比分析,识别丑小鸭痣。
  • 联合丑小鸭征与病灶聚焦分析可提高特异性并减少不必要的活检。

局限性

  • 研究采用数字图像回放,非真实临床场景。
  • 样本仅来自80例患者和9名医生,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Understanding the contribution of the ugly duckling sign (a nevus that is obviously different from the others in a given individual) in intrapatient comparative analysis (IPCA) of nevi may help improve the detection of melanoma. OBJECTIVES: To assess the agreement of dermatologists on identification of the ugly duckling sign and estimate the contribution of IPCA to the diagnosis of melanoma. DESIGN, SETTING, AND PARTICIPANTS: The same 2089 digital images of the nevi of a sample of 80 patients (mean age, 42 years [range, 19-80 years]; 33 men and 47 women), as well as 766 dermoscopic images from a subset of 30 patients (mean age, 40 years [range, 21-75 years]; 12 men and 18 women), were randomly presented to the same 9 dermatologists for blinded assessment from September 22, 2011, to April 1, 2013. The first experiment was designed to mimic an IPCA situation, with images of all nevi of each patient shown to the dermatologists, who were asked to identify ugly duckling nevi (UDN). The second experiment was designed to mimic a lesion-focused analysis to identify morphologically suspicious nevi. Data analysis was conducted from November 1, 2012, to June 1, 2013. MAIN OUTCOMES AND MEASURES: Number of nevi labeled UDN and morphologically suspicious nevi, specificity of lesion-focused analysis and IPCA, and number of nevi identified for biopsy. RESULTS: Of the 2089 clinical images of nevi from 80 patients (median number of nevi per patient, 26 [range, 8-81]) and 766 dermoscopic images (median number of nevi per patient, 19 [range, 8-81]), all melanomas were labeled UDN and as morphologically suspicious nevi by the 9 dermatologists. The median number of UDN detected per patient was 0.8 among the clinical images of nevi (mean, 1.0; range, 0.48-2.03) and 1.26 among the dermoscopic images (mean, 1.4; range, 1.00-2.06). The propensity to consider more or fewer nevi as having ugly duckling signs was independent of the presentation (clinical or dermoscopic). The agreement among the dermatologists regarding UDN was lower with dermoscopic images (mean pairwise agreement, 0.53 for clinical images and 0.50 for dermoscopic images). The specificity of IPCA was 0.96 for clinical images and 0.95 for dermoscopic images vs 0.88 and 0.85, respectively, for lesion-focused analysis. When both IPCA and lesion-focused analyses were used, the number of nevi considered for biopsy was reduced by a factor of 6.9 compared with lesion-focused analysis alone. CONCLUSIONS AND RELEVANCE: Intrapatient comparative analysis is of major importance to the effectiveness of the diagnosis of melanoma. Introducing IPCA using the ugly duckling sign in computer-assisted diagnosis systems would be expected to improve performance.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Gaudy-Marqueste C, Wazaefi Y, Bruneu Y, et al. Ugly Duckling Sign as a Major Factor of Efficiency in Melanoma Detection. JAMA Dermatol. 2017. PMID: 28196213. doi:10.1001/jamadermatol.2016.5500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。